Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05660850 · ClinicalTrials.gov registry record · Phase 2
A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT05660850 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 49 participants.
The verdict
NCT05660850, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic (PD) effects of GDC-6599 compared with placebo in patients with a history of chronic cough.
Interventions
- DRUG GDC-6599
- OTHER GDC-6599-matching placebo
- DIAGNOSTIC_TEST Mannitol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2023-03-22 |
| Est. Completion | 2024-10-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05660850
The ClinicalTrials.gov registry entry for NCT05660850 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which GDC-6599 is the first listed.
NCT05660850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05660850 about?
NCT05660850 is a clinical study titled "A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough". This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic (PD) effects of GDC-6599 compared with placebo in patients with a history of chronic cough.
What is the current status of trial NCT05660850?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2023-03-22. Estimated completion is 2024-10-20.
What interventions are being tested in trial NCT05660850?
The interventions under investigation include: GDC-6599 (DRUG), GDC-6599-matching placebo (OTHER), Mannitol (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05660850?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.